Related Experiment Video

Updated: Nov 20, 2025

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.3K

The Effect of Enhanced External Counterpulsation on Platelet Aggregation in Patients with Coronary Heart Disease

Yating Wang1, Danyan Xu2

  • 1Department of Cardiovascular Medicine, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China.

Cardiovascular Drugs and Therapy
|January 21, 2021
PubMed

Insights

Enhanced external counterpulsation (EECP) therapy effectively lowers platelet aggregation in patients with coronary heart disease (CHD). This noninvasive treatment is particularly beneficial for reducing arachidonic acid-induced platelet aggregation.

Area of Science:

  • Cardiology
  • Vascular Biology
  • Platelet Physiology

Background:

  • Coronary heart disease (CHD) patients often exhibit resistance to antiplatelet therapies like aspirin and clopidogrel.
  • Enhanced external counterpulsation (EECP) is a noninvasive treatment with known benefits for CHD.
  • The precise physiological mechanisms and impact of EECP on platelet function in CHD remain insufficiently understood.

Purpose of the Study:

  • To investigate the effects of EECP on platelet aggregation in patients with coronary heart disease (CHD).
  • To determine if EECP influences specific pathways of platelet activation, such as arachidonic acid (AA) induced aggregation.

Main Methods:

  • A randomized controlled trial involving 168 CHD patients was conducted.
  • Patients were assigned to either a control group (standard medical treatment) or an EECP group (standard medical treatment plus EECP).
  • Platelet aggregation, specifically the arachidonic acid (AA)-induced maximum aggregation ratio (MAR), was measured at baseline and post-treatment.

Main Results:

  • No significant difference in baseline AA-induced platelet MAR was observed between the control and EECP groups.
  • Following EECP therapy, a significant reduction in AA-induced platelet MAR was noted in the EECP group.
  • Logistic analysis indicated that low HDL-C levels were associated with a less favorable decrease in platelet aggregation.

Conclusions:

  • Enhanced external counterpulsation (EECP) therapy demonstrates a beneficial effect in reducing platelet aggregation in patients with coronary heart disease (CHD).
  • The therapy is particularly effective in lowering the arachidonic acid (AA)-induced platelet aggregation ratio.
Abstract

Keywords:
Coronary heart diseaseEnhanced external counterpulsationPlatelet aggregation

More Related Videos

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation09:13

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation

Published on: April 6, 2017

12.3K
Author Spotlight: Innovative Techniques for ROS Detection and Implications for Platelet Research06:35

Author Spotlight: Innovative Techniques for ROS Detection and Implications for Platelet Research

Published on: March 29, 2024

925

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
857
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
124
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
115
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
135
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
150
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
96